FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
All XRAYs
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Study : Resistant starch may help prevent some cancers in people with Lynch syndrome
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with Lynch syndrome and people with a personal and/or family history that suggests Lynch syndrome
This study looked at whether a type of nutrient known as resistant starch could lower the risk of cancers in people with Lynch Syndrome. Researchers found that resistant starch can reduce the risk of non-colorectal cancers but not colorectal cancer. (Posted 10/17/22)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Study : Teens and young adults respond well to learning about familial cancer risk
Relevance: Medium-High
Strength of Science: Medium-High
Most relevant for: Mothers who have had genetic testing for BRCA1 or BRCA2 whether or not they have been diagnosed with breast or ovarian cancer
Little is known about how awareness of hereditary cancer in a high-risk family affects the quality of life of teens and young adults. This study looked at the lifestyle choices, cancer awareness and quality of life of adolescents and young adults whose mothers had undergone testing for a BRCA mutation. (Posted 10/11/2022) Este artículo está disponible en español.
Read More
Update : PARP inhibitors withdrawn as third-line or later treatment for recurrent ovarian cancer
Most relevant for: people with recurrent ovarian cancer who have received 3 or more prior lines of treatment and who have an inherited or tumor mutation in BRCA1 or BRCA2 or whose tumor is HRD positive
Survival data from a clinical trial signaled that PARP inhibitors may not work as well as chemotherapy for patients with recurrent ovarian cancer who have received three or more lines of treatment. As a result, FDA approvals have been withdrawn for PARP inhibitors in this setting. This does not affect PARP inhibitor approvals for use as maintenance therapy for ovarian cancer. (Posted 10/4/22)
Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Acupuncture may ease breast cancer treatment side effects
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: People considering acupuncture for managing breast cancer treatment symptoms.
Acupuncture can ease some symptoms of breast cancer treatment. Multiple studies found that acupuncture is a safe and effective strategy to manage certain symptoms but also called for more rigorous research on the topic. (Posted 9/28/22) Este artículo está disponible en español.
Read More
Update : FDA reports on new cancers linked to breast implants
Most relevant for: People with breast implants
New cancers have been found in women with both textured and smooth implants that are filled with either saline or silicone. These cancers are extremely rare. The FDA has reported cases of a type of skin cancer and blood cancers in the scar tissue that forms around breast implants. The newly reported lymphomas are different from the previously reported breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). (Posted 9/27/22). Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Study : Expanding Medicaid reduced racial disparities among people with metastatic breast cancer
Relevance: Medium-High
Strength of Science: Medium-High
Most relevant for: People diagnosed with de novo stage 4 breast cancer and people who live in states that have not expanded Medicaid.
The Affordable Care Act allowed more people to access insurance through Medicaid. This study found the expansion of care improved survival and decreased mortality among people of color with de novo stage 4 (stage 4 at the time of initial diagnosis) breast cancer. (Posted 9/13/2022). Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Study : PARP inhibitor treatment for metastatic prostate cancer shows most benefit in men with inherited BRCA mutations
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Most relevant for: People with metastatic castration resistant prostate cancer who have an inherited or tumor mutation in BRCA2.
This study looked at the benefit of using the PARP inhibitor niraparib to treat metastatic castration-resistant prostate cancer (mCRPC). Participants included those with an inherited or tumor mutation in BRCA1 or BRCA2 or an inherited or tumor mutation in another gene that affects DNA repair. Participants with an inherited or tumor mutation in BRCA1 or BRCA2 had better survival compared to those without a BRCA mutation. Side effects from niraparib were common, and consistent with previous reports for PARP inhibitors. (posted 9/6/2022)
Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Study : Screening for pancreatic cancer detects early-stage disease and improves survival
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People at increased risk for pancreatic cancer because of family history or an inherited mutation.
A research study has shown that screening for pancreatic cancer in people with an inherited mutation or family history was able to detect early-stage pancreatic cancers and improve survival. These results will likely change pancreatic cancer screening guidelines for high-risk individuals (Posted 8/30/22)
Este artículo está disponible en español.
Read More
Study : Clinical trial eligibility excludes more Black than white patients
Most relevant for: People with pancreatic cancer who are interested in participating in a clinical trial
Eligibility criteria stating who can and cannot participate in clinical trials are necessary. However, traditional eligibility criteria have led to the exclusion of Black people in pancreatic cancer clinical trials. This exclusion restricts patient access to new drugs and limits the ability to generalize results to the population of patients who will ultimately use the drug. Revising eligibility criteria, especially for patients with pancreatic cancer, may improve clinical trial access among Black people. (Posted 8/23/22)
Este artículo está disponible en español.
Read More
Article : Rise in endometrial cancer affects Black women more than white women
Most relevant for: People concerned about their risk for endometrial cancer
The New York Times calls attention to the increase in a type of cancer of the uterus called endometrial cancer and how it disproportionately affects Black women. The article provides useful information about endometrial cancer while raising awareness of a significant and growing health disparity. (Posted 8/16/22)
Este artículo está disponible en español.
Read More